Crucially, vaccine-based therapeutic modalities targeting PDGFRA offer a compelling dual strategy: they hold the potential to suppress tumor proliferation while simultaneously reversing immune evasion mechanisms. This evidence concerns the gene PDGFRA and neoplasm.